

Test Report: Commercial in Confidence

Fera Science Ltd,
Sand Hutton,
York,
YO41 1LZ
United Kingdom



Test Report No.: FR002212_S20017395

Date: 19th May 2020

Customer:	Elixinol BV
Analysis 1:	Suite of cannabinoids by LC-MS/MS
Analysis 2:	Cannabidiol (CBD) by HPLC-UV
Matrix:	CBD capsules_Allure TA2002 06
Received:	6 th of May 2020
Analysed	7 th to 12 th of May 2020

1. BACKGROUND

This report describes the analytical testing of a CBD sample product.

The term "CBD" is an acronym for cannabidiol, which is one of several cannabinoids, or chemical compounds, that are found in cannabis and hemp plants.

The sample was analysed for the concentrations of 14 cannabinoids:

- **CBC**, Canabichromene
- **CBC-A**, Cannabichromenic acid
- **CBD**, Cannabidiol
- **CBD-A**, Cannabidiolic acid
- **CBDV**, Cannabidivarin
- **CBDV-A**, Cannabidivarinic acid
- **CBG**, Cannabigerol
- **CBG-A**, Cannabigerolic acid
- **CBN**, Cannabinol
- **Δ8-THC**, Delta-8-Tetrahydrocannabinol
- **Δ9-THC**, Delta-9-Tetrahydrocannabinol
- **THC-A**, Tetrahydrocannabinolic acid
- **THCV**, Tetrahydrocannabivarin
- **THCV-A**, Tetrahydrocannabivarinic acid

Test Report: Commercial in Confidence

2. SAMPLE DESCRIPTION

The sample was received at the laboratory in satisfactory condition and stored at ambient temperature prior to analysis.

The sample was received in the manufacturers packaging consisting of a glass bottle with a screw cap within a cardboard outer box.

A unique identifying number was assigned to the sample using the Fera laboratory information management system. The relevant sample details are shown in the table below.

Sample information				
Fera reference	Customer reference	Description	Batch/LOT code	Best before
S20-017395	Allure	Allure, CBD capsules. 150 mg CBD. +Niacin, +Selenium. 30 capsules.	TA2002 06	02.2022

3. SAMPLING AND ANALYSIS

3.1 Cannabinol (CBN), delta-9-tetrahydrocannabinol (Δ 9-THC), delta-8-tetrahydrocannabinol (Δ 8-THC), tetrahydrocannabinolic acid (THC-A), tetrahydrocannabivarin (THCV), canabichromene (CBC), cannabichromenic acid (CBC-A), cannabidiolic acid (CBD-A), cannabidivarin (CBDV), cannabidivarinic acid (CBDV-A), cannabigerol (CBG), cannabigerolic acid (CBG-A) and tetrahydrocannabivarinic acid (THCV-A)

The sample was extracted into solvent and diluted before the cannabinoids were determined using LC-MS/MS. Accuracy of the method was assessed by analysing over spiked blank material alongside the samples.

3.2 Cannabidiol (CBD)

The sample was extracted into solvent and diluted before the cannabidiol was determined using LC-UV. Accuracy of the method was assessed by analysing in-house reference materials with known concentrations of CBD.

Test Report: Commercial in Confidence

4. RESULTS

Sample identification: Allure TA2002-06

Fera LIMS: S20-017395

Weight of capsule content: 387 mg

Total pack size: 30 capsules

Analyte	% w/w	Mass of analyte per capsule content (mg)	Mass of analyte per pack of 30 capsules (mg)
CBC , Canabichromene	<0.01	<0.04	<1.2
CBC-A , Cannabichromenic acid	<0.01	<0.04	<1.2
CBD , Cannabidiol	0.85	3.3	99
CBD-A , Cannabidiolic acid	<0.01	<0.04	<1.2
CBDV , Cannabidivarin	>0.05	>0.19	>5.8
CBDV-A , Cannabidivarinic acid	<0.01	<0.04	<1.2
CBG , Cannabigerol	0.012	0.05	1.4
CBG-A , Cannabigerolic acid	<0.01	<0.04	<1.2
CBN , Cannabinol	<0.002	< 0.008	< 0.23
Δ8-THC , Delta-8-Tetrahydrocannabinol	<0.002	< 0.008	< 0.23
Δ9-THC , Delta-9-Tetrahydrocannabinol	<0.002	< 0.008	< 0.23
THC-A , Tetrahydrocannabinolic acid	<0.002	< 0.008	< 0.23
THCV , Tetrahydrocannabivarin	0.035	0.13	4.0
THCV-A , Tetrahydrocannabivarinic acid	<0.002	<0.008	<0.23
Total THC [Δ9-THC + (THC-A x 0.887)]	<0.004	<0.015	<0.5
Total CBD [CBD + (CBD-A x 0.887)]	0.85	3.3	99

Test Report: Commercial in Confidence

Issuing Officer:	Mark Harrison, Analytical chemist	Date:	19/05/20
Countersigning Manager:	Rosario Romero, Senior analytical chemist Michael Dickinson, Senior analytical chemist	Date:	19/05/20

This report has been prepared by Fera Science Limited ("Fera") for the for the sole benefit of Elixinol BV. This document, and all the information, images and intellectual property rights in it belong to Fera (or its licensees). No part of the text or graphics may be reproduced without the prior written permission of Fera. Except as otherwise advised in writing by Fera, this information is confidential in nature must be treated by the receiver with at least the degree of care that it applies to its own confidential information (and always with at least a reasonable standard of care).

Fera shall not be liable for any claims, losses, demands or damages of any kind whatsoever (whether such claims, losses, demands or damages were foreseeable, known or otherwise and whether direct, indirect or consequential) arising out of or in connection with: (i) any advice given by Fera or its representatives; and/or (ii) the preparation of any technical or scientific reports. Fera makes no representation as to the suitability of using any particular goods in any manufacturing processes or scientific research, nor as to their use in conjunction with any other materials. Fera shall not be liable for any reliance placed on, nor for any recommendations, interpretation, analysis, guidance, suggestions, proposals or endorsements made in connection with, the services and/or the commercial or scientific activities carried out by Fera or its representatives.

© 2020 Fera Science Limited